Abstract | OBJECTIVE: RESULTS:
Dysmenorrhea and noncyclic pelvic pain were relieved in 48/52 (92.3%) and 25/28 (89.2%) of patients, respectively. Overall pain relief was obtained in 49/52 (94.2%) of patients. Breakthrough bleeding, of variable severity, was the most common side effect experienced by 30 patients (57.6%); however, only 4 patients (7.7%) dropped out for this side effect. One other patient dropped out for severe breast tenderness, and three for noncyclic pelvic pain. In general, treatment was successful in 44/52 (84.5%) of patients with the above symptoms. CONCLUSION: NA seems to be a cost-effective alternative with relatively mild side effects in the treatment of symptomatic endometriosis.
|
Authors | O Muneyyirci-Delale, M Karacan |
Journal | International journal of fertility and women's medicine
(Int J Fertil Womens Med)
1998 Jan-Feb
Vol. 43
Issue 1
Pg. 24-7
ISSN: 1534-892X [Print] United States |
PMID | 9532466
(Publication Type: Journal Article)
|
Chemical References |
- Progesterone Congeners
- Norethindrone
|
Topics |
- Adult
- Endometriosis
(drug therapy)
- Female
- Humans
- Norethindrone
(adverse effects, therapeutic use)
- Patient Dropouts
- Progesterone Congeners
(adverse effects, therapeutic use)
- Retrospective Studies
- Treatment Outcome
- Uterine Hemorrhage
(chemically induced)
|